Prognostic value of Lynch syndrome, BRAF<sup>V600E</sup> , and RAS mutational status in dMMR/MSI-H metastatic colorectal cancer in a pooled analysis of Dutch and French cohorts.

Cancer Med · 2023 · PMC10469760 · PMID 37326121

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

4 , 13 , 16 Patients with tumors harboring a RAS mutation showed a trend towards better prognosis in univariate analysis, which is remarkable compared to the known inferior prognosis of RAS mutations in pMMR/MSS mCRC patients. 10 However, in dMMR/MSI‐H mCRC patients this could also be explained by the strong association between patients with RAS ‐mutated tumors and Lynch syndrome and younger age.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.